Table 1.
Baseline characteristics.
| Patients (n = 20) | |
|---|---|
| Men | 19 (95%) |
| Age [years] | 37.4±9.3 |
| BMI [kg/m2] | 22.8 ±2.8 |
| HCV RNA [IU/ml] | 104,307 (7,842–1,726,734) |
| <50,000 | 8 (40%) |
| <10 | 2 (10%) |
| HCV genotype | |
| 1a | 12 (60%) |
| 1b | 1 (5%) |
| 2 | 1 (5%) |
| 3 | 3 (15%) |
| 4 | 3 (15%) |
| Patients with oral HIV pre-exposure prophylaxis | 13 (65%) |
| Patients with substitution treatment | 2 (10%) |
| Patients with confirmed HCV reinfection | 1 (5%) |
| Liver enzymes | |
| Alanine aminotransferase [U/L] | 249 (165–463) |
| Aspartate aminotransferase [U/L] | 133 (71–219) |
| Bilirubin [U/L] | 12.0 (8.0–17.1) |
| Gamma-glutamyltransferase [U/L] | 93 (52–160) |
Values as median (interquartile range) or mean ± SD.